Insitro
Data-driven drug discovery and development company using machine learning and high-throughput biology.
About
Insitro is a data-driven drug discovery and development company that leverages machine learning and high-throughput biology to transform the way medicines are created. They are rethinking the entire drug discovery process from the perspective of machine learning and human genetics to develop novel therapeutics. Teams look it up for Healthcare, Drug Discovery, Drug Development.
Frequently asked
What does Insitro do?
Insitro is a Healthcare company that offers Software. Teams look it up for Drug Discovery, Drug Development, DNA. It is based in South San Francisco, United States and was founded in 2018. Public records show about 255 people and $243M raised. Compare it on funding, headcount, reviews and nearby alternatives rather than the marketing line alone.
How much funding has Insitro raised?
Insitro has raised a total of $243M in funding. The most recent round on record is Series B.
Where is Insitro headquartered?
Insitro is headquartered in South San Francisco, United States.
When was Insitro founded?
Insitro was founded in 2018.
What industry does Insitro operate in?
Insitro operates in Healthcare, Drug Discovery, Drug Development, DNA, Next Generation Sequencing.
How many employees does Insitro have?
Insitro has approximately 255 people on record.
AI-driven drug discovery platform
Both companies leverage AI and machine learning for drug discovery and development, aiming to accelerate the identification of novel therapeutics.
Recursion OS (AI-driven drug discovery platform)
Both Insitro and Recursion Pharmaceuticals utilize machine learning and high-throughput biology to discover and advance drug candidates.
Internal R&D and collaborations in drug discovery
While a partner, Bristol Myers Squibb also conducts its own drug discovery and development, including leveraging AI, which could be seen as a competing approach to Insitro's platform-as-a-service model for other clients.
Lilly TuneLab™ (drug discovery platform)
Eli Lilly, a partner of Insitro, also develops its own drug discovery platforms like Lilly TuneLab™ that provide biotechs access to machine learning models, creating a competitive offering in the broader market.
Large Pharmaceutical Companies
Gilead has an existing strategic collaboration with Insitro for NASH, indicating a continued interest in leveraging Insitro's platform for other therapeutic areas and expanding their partnership.
Large Pharmaceutical Companies
Bristol Myers Squibb has an ongoing collaboration with Insitro for ALS, demonstrating their reliance on Insitro's AI-driven platform for target discovery and molecule design in neurodegenerative diseases.
Confirmed customer relationships for Insitro. Speculative buyer-fit guesses are not shown.
Strength of the site’s backlink profile, on Ahrefs’ 0-100 Domain Rating scale. Licensed third-party data, not our opinion.
How well an AI agent can read and use this site: structured data, clean markup, and whether key facts are reachable without running JavaScript. We scan the live site.